Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Observational × surufatinib × Clear all

Status

Sponsor Class

Study Type

Interventional 23 Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumor Grade 3 1

Interventions

Blood Specimen Collection 72 Surveys and Questionnaires 71 Surgical Procedures, Operative 36 Drug Therapy 26 Radiotherapy 23 Amplified Fragment Length Polymorphism Analysis 21 Biopsy 20 Neoadjuvant Therapy 18 Gene Expression Profiling 18 Immunohistochemistry 17 Bevacizumab 17 Liquid Biopsy 15 pembrolizumab 14 Ultrasonography 14 Positron Emission Tomography Computed Tomography 14 Nivolumab 14 Radiosurgery 13 Immunotherapy 13 Capecitabine 13 Watchful Waiting 12 Observation 12 Magnetic Resonance Spectroscopy 12 Magnetic Resonance Imaging 12 Data Collection 12 Oxaliplatin 11 Microarray Analysis 11 Interviews as Topic 11 Trastuzumab 10 Polymerase Chain Reaction 10 Colonoscopy 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡